Key result
Topoisomerase 2β is a promising molecular target for designing interventions to prevent anthracycline-induced cardiotoxicity, as its deletion in cardiomyocytes prevents cardiotoxicity in mice.
Why the study?
Does targeting Topoisomerase 2β prevent anthracycline-induced cardiotoxicity?
Does targeting Topoisomerase 2β prevent anthracycline-induced cardiotoxicity?
Topoisomerase 2β is identified as a critical mediator of anthracycline-induced cardiotoxicity and a promising target for future cardioprotective strategies.
No takes yet. Share an insight, caveat, or question.
Should not change anthracycline cardioprotection practice; hypothesis-generating for Top2β-targeted prevention pending human translation.
Vejpongsa et al. (2013) conducted a review in Anthracycline-induced cardiotoxicity. Topoisomerase 2β targeting was evaluated. Topoisomerase 2β is a promising molecular target for designing interventions to prevent anthracycline-induced cardiotoxicity, as its deletion in cardiomyocytes prevents cardiotoxicity in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: